629plapatinib versus Lapatinib plus Capecitabine as Second-line Treatment in Her2-overexpressing Metastatic Gastro-esophageal Cancer (gc): a Randomized Phase Ii Trial of the Arbeitsgemeinschaft Internistische Onkologie (aio).

S. Lorenzen1, U. Helbig2, J. Riera-Knorrenschild3, G.M. Haag4, M. Pohl5, P. C. Thuss-Patience6, F. Bassermann1, F. Weißinger7, E. Schnoy8, K. Becker9, J. Rüschoff10, A. Eisenmenger11, I. Karapanagiotou-Schenkel11, F. Lordick12 3rd Department of Internal Medicine (hematology/medical Oncology), Klinikum Rechts der Isar, Technische Universität München, Munich, GERMANY 3rd Medical Department, Hematology and Oncology, Klinikum Braunschweig, Braunschweig, GERMANY Clinic for Hematology, Oncology and Immunology, Universitaetsklinikum Giessen und Marburg, Marburg, GERMANY Department of Medical Oncology, National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, GERMANY Department of Medicine, Knappschaftskrankenhaus, Ruhr University Bochum, Bochum, GERMANY Department of Hematology, Oncology and Tumor Immunology, Virchow-Klinikum, Charité, Berlin, Berlin, GERMANY Department of Medicine, Hematology, Oncology and Palliative Care, Evangelisches Krankenhaus, Bielefeld, Bielefeld, GERMANY Department of Internal Medicine, University Clinic Regensburg, Regensburg, GERMANY Onkologische Praxis, Lerchenfeld, Hamburg, GERMANY Molecular Pathology, Targos, Kassel, GERMANY NCT Trial Center, National Center for Tumor Diseases, Heidelberg, Heidelberg, GERMANY University Cancer Center Leipzig, University of Leipzig, Leipzig, GERMANY